Visiongain Reports Ltd
Visiongain has published a new report entitled Global Genome Editing Technologies Market, (COVID-19 Impact Analysis):- Market Segment by Type (CRISPR, TALEN, ZFN, Antisense, Others), Market Segment by Application (Cell Line Engineering, Genetic Engineering, Diagnostic applications, Drug discovery & development, Others), Market Segment by End-user (Biotechnology companies, Pharmaceutical companies, Academic & Government Research Institutes, Others) plus COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped), Profiles of Leading Companies, Region and Country.
The Global Genome Editing Technologies market is estimated to be valued at US$ 4,225.48 million in 2022. The market is projected to reach a market value of US$ 18,570.41 million by 2032. We predict strong revenue growth through to 2032
Download Sample here -https://www.visiongain.com/report/genome-editing-technologies-market-2022/#download_sampe_div
How has COVID-19 had a positive impact on the Genome Editing Technologies Market?
The COVID-19 pandemic has prompted large pharmaceutical and biotechnology firms, as well as genomic market participants, to engage in vaccine research and development. The rising need for vaccines and potential antiviral candidates has propelled genome editing/engineering technologies to the forefront. CRISPR technology was successfully used to provide rapid diagnostic tests for COVID-19, leading in its first FDA clearance (MD, USA). Many firms are rushing to cover the ever-widening market vacuum generated by reagents for PCR-based COVID-19 tests running out and testing capacity dwindling while rapid diagnostic tests are now being developed for wider clinical use. In other areas, researchers have considered CRISPR as a viable therapeutic, utilizing its targeted enzymatic activity to degrade SARS-CoV-2 RNA and halt viral replication."
How will this Report Benefit you?
Visiongains 414-page report provides 154 tables and 279 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the Global Genome Editing Technologies Market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Genome Editing Technologies. Get a financial analysis of the overall market and different segments including gene editing technologies, applications, end-users, and company size, and capture a higher market share. We believe that there are strong opportunities in this fast-growing Genome Editing Technologies market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximize the productivity of the company.
Story continues
What are the Current Market Drivers?
Rising investments in Genome Editing Technologies Governments of numerous nations throughout the world have made large investments in genomics in recent years, which have aided in the development of novel genome editing technologies. Furthermore, the availability of government financing has allowed academic and government institutes to conduct extensive genome editing/engineering research. For instance, in March 2020, Genome Canada received US$ 15 million from the Ministry of Innovation, Science, and Industry (Science) to support 11 genomic research initiatives in the health, agricultural, and environment sectors. Provincial governments, industries, and research partners will contribute a total of US$ 29.7 million to these research projects. The projects involve ovarian and cervical cancer research. The number of genomics research initiatives has increased significantly as a result of major government investments in this sector boosting the genome editing technologies market's growth over the forecast period.
The rise in the incidence of cancer and infectious diseases
Cancer incidence rates are predicted to rise from 20 million new cases per year in 2020 to more than 30 million new cases per year by 2040. Genome editing technologies provide new opportunities in fundamental cancer research and diagnostics, with advantages such as simple design, rapid operation, low cost, and robust scaling, introducing CRISPR/Cas as a rapidly evolving editing technique that is applicable to almost all genomic targets. Several genome editing techniques, including zinc finger endonuclease (ZFN), transcription activator-like effector nuclease (TALEN), and the clustered regularly interspaced short palindromic repeats/CRISPR associated nuclease (CRISPR/Cas) system, have been developed to provide efficient gene editing for the treatment of cancers, infectious diseases, and genetic disorders
Where are the Market Opportunities?
CRISPR Cas9 Technology to widen its applicationCRISPR-Cas9 is one of the most significant discoveries of the twenty-first century. Since its inception in 2012, this gene-editing technology has transformed biology research, making illness research easier and medication discovery faster. The technique is also having a substantial influence on crop development, food production, and industrial fermentation operations. CRISPR-Cas9 technology has huge potential in the pharmaceutical business. Scientists are tackling CRISPR-Cas technology, testing its possibilities and limits as a medical tool. It is being tested for treating diseases in humans such as cancer, blood disorders, blindness, AIDS, and genetic disorder such as Cystic fibrosis, hemophilia, -thalassemia, Alzheimer's, Huntington's, Parkinson's, tyrosinemia, Duchenne muscular dystrophy, Tay-Sachs, and fragile X syndrome disorders.
Competitive LandscapeThe major players operating in the Genome Editing Technologies market are Thermo Fisher Scientific Inc., Merck KGaA, GenScript, Sangamo Therapeutics Inc., Lonza, Editas Medicine, CRISPR Therapeutics AG, Agilent Technologies Inc., Precision Biosciences, and Tecan Life Sciences. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Recent Developments
In April 2022, Thermo Fisher Scientific introduced the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein. TrueCut Cas9 proteins are manufactured with United States Pharmacopeia standards in mind, including traceability documentation, aseptic manufacturing, and safety testing.
In February 2022, CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies have collaborated to address diseases with significant unmet needs, announced the first patient has been dosed in the Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes (T1D)..
To find more Visiongain research reports on the Pharma sector, click on the following links:
Do you have any custom requirements we can help you with?Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:dev.visavadia@visiongain.com
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicatedmarket research reportsoffer a bespoke piece of market intelligence customised to your very own business needs.
Contact:Dev VisavadiaPR at Visiongain Reports LimitedTel: + 44 0207 336 6100Email:dev.visavadia@visiongain.com
Read more here:
Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltd - Yahoo Finance
- Principles of Genetic Engineering - PMC - National Center for ... - March 28th, 2024
- Historic Overview of Genetic Engineering Technologies for Human Gene ... - March 28th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - December 10th, 2023
- Genetically modified organism - Wikipedia - November 16th, 2023
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - November 16th, 2023
- 18 Human Genetic Engineering - Clemson University - April 7th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - April 7th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 12th, 2023
- Genetic Engineering Principles of Biology - December 27th, 2022
- Engineering the Perfect Baby | MIT Technology Review - December 27th, 2022
- What is CRISPR? | Live Science - November 24th, 2022
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 13th, 2022
- DNA and the impossibility of research in isolation - Morning Star Online - October 13th, 2022
- Genome editing technologies: final conclusions of the re-examination of Article 13 of the Oviedo Convention - Council of Europe - October 13th, 2022
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 13th, 2022
- Dissatisfaction and New Articulations - Discovery Institute - October 13th, 2022
- In 'The Cultivar Series,' Uli Westphal Gets to the Root of Crop Diversity and Agricultural Modification - Colossal - October 13th, 2022
- Genomic Research Aids in the Effort to Understand How Best to Treat Deadly Infections Caused by a Fungus - UMass News and Media Relations - October 13th, 2022
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 13th, 2022
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 13th, 2022
- Emily Whitten: The limits of science and human intelligence - WORLD News Group - October 13th, 2022
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 13th, 2022
- Earth materials in technology The National - The National - October 13th, 2022
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 13th, 2022
- Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic... - October 13th, 2022
- Skin Grafting, Cryopreservation, and Diseases: A Review Article - Cureus - October 13th, 2022
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 13th, 2022
- Ignore scary messages: We've never had it so good & that's not manure - West Side Index & Gustine Press-Standard - October 13th, 2022
- Global Phosphoramidite Market Report 2022: Increasing Synthetic Nucleotide Applications in Therapeutics Drives Growth - ResearchAndMarkets.com -... - October 13th, 2022
- Enzymes Market worth $16.9 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - October 4th, 2022
- Experts Sound Alarm Over 'Growing Threat' of Genetically Engineered Trees - Common Dreams - October 4th, 2022
- Scientists are manipulating the DNA of mosquitoes to fight the spread of malaria - Euronews - October 4th, 2022
- Smile Coffee Werks upgraded its coffee beans to Fair Trade and USDA Organic - Vending Market Watch - October 4th, 2022
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 4th, 2022
- 22nd Century Group (Nasdaq: XXII) Expands VLN Distributor Network with the Addition of Specialty Distrib - Benzinga - October 4th, 2022
- Researchers are seeking to develop spuds that resist harmful nematodes - FreshPlaza.com - October 4th, 2022
- Synthetic biology has the power to cure and kill. How will we use it? - Big Think - September 25th, 2022
- SPECIAL REPORT: Bioengineered food labeling: 'They kind of shot in the middle and missed every constituency' - FoodNavigator-USA.com - September 25th, 2022
- Yeast-Fermented Chemo: Now We Can Brew Anything - Medscape - September 25th, 2022
- September 23, 2022: The Integrity of Marius Mason WFHB - WFHB News - September 25th, 2022
- 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years - The Motley Fool - September 25th, 2022
- Bananas threatened by devastating fungus given temporary resistance - New Scientist - September 25th, 2022
- 'What Hath God Wrought' - Today, Luddites Are Concerned About Weedkillers Like They Once Were The Telegraph - Science 2.0 - September 25th, 2022
- Children should be educated about oral health and hygiene - Star of Mysore - September 25th, 2022
- Id rather eat an actual burger: why plant-based meats sizzle fizzled in the US - The Guardian - September 25th, 2022
- Health Tech startups are booming. These 11 VC investors are behind some of the hottest deals - Fortune - September 25th, 2022
- Last Chance This Fall to Tell the NOSB To Uphold Organic Integrity - Beyond Pesticides - September 25th, 2022
- Cambodian PM begins official visit to Cuba - Khmer Times - September 25th, 2022
- Researchers develop method to prevent spread of melanoma to brain - Xinhua - September 25th, 2022
- I'm allergic to the cat, what can I do? - Surinenglish.com - September 25th, 2022
- Researchers Propose a New Way of Regulating Engineered Crops - Modern Farmer - September 16th, 2022
- Purple Tomato is first genetically engineered plant to be deregulated through USDA's new regulatory status review process - Lexology - September 16th, 2022
- Genetically Modified Feed Market to Hit $135 billion by 2030, says Global Market Insights Inc. - Yahoo Finance - September 16th, 2022
- Africa, GMOs and Western Interests - DW (English) - September 16th, 2022
- The science behind the oil supply breakdown in 'Last Light' - Syfy - September 16th, 2022
- Inside the controversial plan to bring extinct animals back from the dead - The Independent - September 16th, 2022
- Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character - Giant Freakin Robot - September 16th, 2022
- Scientists closer to making blood stem cells in the lab - Cosmos - September 16th, 2022
- Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight - Digital Journal - September 16th, 2022
- Don't call it waste - it can be turned into hydrogen if you handle it right - Innovation Origins - September 16th, 2022
- Can gene editing ease the cost of living crisis? - The Grocer - September 8th, 2022
- Gene editing could revive the American chestnut tree and help fight climate change but familiar anti-biotechonology activist critics will have none... - September 8th, 2022
- Colossal to de-extinct the Tasmanian tiger. Is it a safe thing to do? - Cape Cod Times - September 8th, 2022
- The Future of Nanotech, the World's Tiniest Industry - Entrepreneur - September 8th, 2022
- Viewpoint: The 'natural food' sham 'Effective communication on the ethics of science may be hindered by appeals to naturalness' - Genetic Literacy... - September 8th, 2022
- Toray says it has developed the worlds first 100% bio-based adipic acid - Biofuels Digest - September 8th, 2022
- Chinese scientists claim to have engineered the world's first mouse with fully reprogrammed genes - Interesting Engineering - August 30th, 2022
- Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to... - August 30th, 2022
- Living Carbon: The startup setting down roots from 9 to 5 | Greenbiz - GreenBiz - August 30th, 2022
- Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through... - August 30th, 2022
- Genetics in fiction - Wikipedia - August 14th, 2022
- Weeds superpower could help feed the planet - Freethink - August 14th, 2022
- POSEIDA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - August 14th, 2022
- Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma - Genetic Engineering & Biotechnology News - August 14th, 2022
- LETTER TO THE EDITOR: Lessons from 1984 | Letters To Editor | carolinacoastonline.com - Carolinacoastonline - August 14th, 2022
- How Arkeon Biotechnologies is turning CO2 into food: 'Excuse my language, but this is next-level cool' - FoodNavigator.com - August 14th, 2022
- Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire - August 14th, 2022
- THE SAD STORY OF THE REJECTION OF SCIENCE - Sp Supplements - DAWN.COM - DAWN.com - August 14th, 2022
- I Got Critiqued by YouTuber Gutsick Gibbon - Discovery Institute - August 5th, 2022
- CRISPR Technology in the Agricultural Industry: Patent and Regulatory Updates - JD Supra - August 5th, 2022